Accenture (ACN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
12 Dec, 2025Executive summary
Annual general meeting scheduled for January 28, 2026, in Dublin, Ireland, with a record date of December 1, 2025.
Strategy centers on being the reinvention partner of choice, leveraging AI and digital transformation, and delivering 360° value to stakeholders.
Fiscal 2025 saw $69.7B in revenue (7% growth), $12.15 EPS (6% growth), $10.9B free cash flow, and $8.3B returned to shareholders.
Board recommends voting FOR all proposals, including director appointments, executive compensation, share incentive plan, auditor ratification, and Irish law proposals.
Voting matters and shareholder proposals
Proposals include appointment of 10 directors, non-binding vote on executive compensation, approval of amended share incentive plan, ratification of KPMG as auditor, and standard Irish law proposals on share issuance and treasury shares.
Board recommends FOR all proposals; voting can be done online, by phone, mail, or QR code.
Shareholders holding 10%+ of shares can call special meetings; proxy access and advance notice provisions are in place.
Board of directors and corporate governance
Board consists of 10 members, 90% independent, with an average tenure of 6 years; four new directors added in the past three years.
Strong focus on diversity of skills, backgrounds, and global experience; director overboarding policy enforced.
Board leadership includes a combined chair/CEO and an independent lead director; all committees are fully independent.
Annual board and committee evaluations, director orientation, and ongoing education are standard.
Shareholder engagement is ongoing, with feedback shaping governance practices.
Latest events from Accenture
- Q2 FY26 delivered record bookings, 8% revenue growth, and higher shareholder returns.ACN
Q2 202619 Mar 2026 - AI strategy is evolving rapidly, with ROI, specialization, and change management as top priorities.ACN
Fireside chat18 Mar 2026 - Q3 bookings hit $21.1B, GenAI surged, and FY24 guidance signals steady growth.ACN
Q3 20243 Feb 2026 - Record bookings, margin expansion, and robust FY25 outlook highlight strong momentum.ACN
Q4 202420 Jan 2026 - Q1 FY25 revenue up 9% to $17.7B; EPS, margin, and dividend rose, outlook raised.ACN
Q1 202510 Jan 2026 - Revenue up 6%, bookings up 12%, adjusted EPS up 10%, strong cash flow and returns.ACN
Q1 202618 Dec 2025 - Board recommends approval of all director, compensation, auditor, and share issuance proposals.ACN
Proxy Filing12 Dec 2025 - Proxy covers 2025 AGM proposals, board refresh, pay-for-performance, and ESG leadership.ACN
Proxy Filing1 Dec 2025 - Fiscal 2024 saw record bookings, board refreshment, and major ESG progress, with all proposals recommended for approval.ACN
Proxy Filing1 Dec 2025